RxDoctor Payments Data

Mary Lee Villanueva, MD

Hematology & Oncology · Yankton, SDNPI 1699857821

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.7% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Lilly USA, LLC at 52.5% of the total. Reporting peaked in 2023 at $174 and has fallen 54.9% since, to $78 in 2024. That places this record below the midpoint for hematology & oncology clinicians in SD, where the typical reported total is $811.

$412in general payments, 2019–2025

Across 22 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$216
  • Amgen$104
  • Genentech USA, Inc.$28
  • Jazz Pharmaceuticals Inc.$20
  • Pfizer$18
  • Acrotech Biopharma Inc.$14
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$38794%
  • Education$266%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$412 in reported general payments places this provider in the 35th percentile of 28 hematology & oncology providers in South Dakota.

See all hematology & oncology providers in South Dakota

Medicare billing

Part B allowed, 2024
$5,288,073
Medicare patients
409
Services billed
256,706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SprycelDasatinib12$193,645
IbrancePalbociclib12$189,978
BrukinsaZanubrutinib11$172,360
ImbruvicaIbrutinib11$159,015
EliquisApixaban11$5,798
Abiraterone Acetate11$4,604
Anastrozole96$1,258
Exemestane18$1,253
Letrozole91$977
Dexamethasone15$278
Potassium Chloride15$238
Ondansetron Hcl17$237
Levothyroxine Sodium27$137
Prochlorperazine Maleate17$128
Omeprazole18$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$18$195,77523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 28 hematology & oncology providers in South Dakota.

Other hematology & oncology in Yankton

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →